Oral Immunization with
COVID-19
IgA
engineered probiotics
oral vaccine
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
21 03 2023
21 03 2023
Historique:
received:
15
01
2023
revised:
04
03
2023
accepted:
14
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
As of October 2022, the COVID-19 pandemic continues to pose a major public health conundrum, with increased rates of symptomatic infections in vaccinated individuals. An ideal vaccine candidate for the prevention of outbreaks should be rapidly scalable, easy to administer, and able to elicit a potent mucosal immunity. Towards this aim, we proposed an engineered
Identifiants
pubmed: 36979504
pii: biom13030569
doi: 10.3390/biom13030569
pmc: PMC10046078
pii:
doi:
Substances chimiques
spike protein, SARS-CoV-2
0
Spike Glycoprotein, Coronavirus
0
COVID-19 Vaccines
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Lab Invest. 1993 Aug;69(2):238-49
pubmed: 8350599
Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
NPJ Vaccines. 2021 Feb 22;6(1):28
pubmed: 33619260
Infect Immun. 2005 Mar;73(3):1452-65
pubmed: 15731043
Curr Opin Biotechnol. 2020 Oct;65:171-179
pubmed: 32304955
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Vaccine. 2014 Nov 20;32(49):6711-23
pubmed: 25454857
Nat Commun. 2019 May 15;10(1):2174
pubmed: 31092823
Front Med (Lausanne). 2022 Oct 13;9:940454
pubmed: 36313997
J Ind Microbiol Biotechnol. 2012 Mar;39(3):383-99
pubmed: 22252444
J Pharmacol Pharmacother. 2010 Jul;1(2):87-93
pubmed: 21350616
J Med Virol. 2022 May;94(5):1825-1832
pubmed: 35023191
Clin Vaccine Immunol. 2012 Feb;19(2):209-18
pubmed: 22190392
J Infect Dis. 2020 Nov 13;222(12):1974-1984
pubmed: 32910175
Eur J Immunol. 2016 Oct;46(10):2426-2437
pubmed: 27457183
Appl Microbiol Biotechnol. 2019 May;103(10):3941-3953
pubmed: 30915504
Microb Cell Fact. 2012 Sep 03;11:118
pubmed: 22943700
Microb Biotechnol. 2022 Mar;15(3):721-737
pubmed: 34962710
Expert Rev Vaccines. 2015 Jun;14(6):861-76
pubmed: 25797360
Front Physiol. 2017 Jul 31;8:520
pubmed: 28824441
Cold Spring Harb Protoc. 2017 Nov 1;2017(11):pdb.prot100271
pubmed: 29093207
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
EBioMedicine. 2022 Jan;75:103788
pubmed: 34954658
Front Immunol. 2021 Jan 19;11:599637
pubmed: 33542716
Curr Opin Virol. 2019 Aug;37:16-25
pubmed: 31163292
Virus Res. 2020 Oct 15;288:198141
pubmed: 32846196
J Infect Dis. 2005 Jul 1;192(1):166-9
pubmed: 15942907
Pilot Feasibility Stud. 2018 Apr 23;4:79
pubmed: 29713493
Curr Opin Infect Dis. 2021 Jun 1;34(3):181-186
pubmed: 33899752
Proc Natl Acad Sci U S A. 2021 May 4;118(18):
pubmed: 33858942
Immunity. 2020 Mar 17;52(3):557-570.e6
pubmed: 32160523
Lancet Infect Dis. 2022 Jan;22(1):16
pubmed: 34953540
Nature. 1975 Jun 5;255(5508):500-2
pubmed: 1094297
FEMS Immunol Med Microbiol. 2005 Mar 1;43(3):373-84
pubmed: 15708311
Am J Med. 2022 Feb;135(2):133-134
pubmed: 34562412
Nutr Rev. 2010 Aug;68(8):459-64
pubmed: 20646223
PLoS One. 2012;7(10):e47069
pubmed: 23056583
Curr Pharm Biotechnol. 2011 Feb 1;12(2):268-74
pubmed: 21050165
Eur J Microbiol Immunol (Bp). 2020 Mar 17;10(1):11-19
pubmed: 32363034
Am J Trop Med Hyg. 2021 Jan 07;104(3):794-796
pubmed: 33427194
Front Immunol. 2013 Jul 12;4:185
pubmed: 23874333
Elife. 2015 Mar 25;4:
pubmed: 25807083
Vaccines (Basel). 2021 May 06;9(5):
pubmed: 34066443
J Med Virol. 2021 Dec;93(12):6765-6777
pubmed: 34387884
Front Microbiol. 2018 Apr 26;9:783
pubmed: 29755431
Front Microbiol. 2022 Apr 26;13:854630
pubmed: 35558112